COMPASS Pathways (NASDAQ:CMPS - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, July 31st. Analysts expect COMPASS Pathways to post earnings of ($0.41) per share for the quarter.
COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
COMPASS Pathways Stock Performance
Shares of NASDAQ:CMPS traded down $0.04 on Friday, reaching $4.33. The company's stock had a trading volume of 1,073,171 shares, compared to its average volume of 2,465,399. The stock has a market capitalization of $405.11 million, a P/E ratio of -2.18 and a beta of 2.12. COMPASS Pathways has a 52-week low of $2.25 and a 52-week high of $8.54. The stock's 50-day moving average is $4.01 and its two-hundred day moving average is $3.78. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.18 and a quick ratio of 10.18.
Institutional Trading of COMPASS Pathways
A hedge fund recently raised its stake in COMPASS Pathways stock. Acadian Asset Management LLC increased its position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 42.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 240,591 shares of the company's stock after acquiring an additional 71,112 shares during the quarter. Acadian Asset Management LLC owned approximately 0.26% of COMPASS Pathways worth $686,000 as of its most recent filing with the SEC. 46.19% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on CMPS shares. Evercore ISI restated an "in-line" rating and set a $6.00 target price (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. HC Wainwright restated a "buy" rating and set a $45.00 target price on shares of COMPASS Pathways in a research report on Tuesday, July 15th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $12.00 target price on shares of COMPASS Pathways in a research report on Tuesday, May 27th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, COMPASS Pathways currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.
Read Our Latest Stock Analysis on COMPASS Pathways
About COMPASS Pathways
(
Get Free Report)
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Featured Stories
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access